Targeting regulatory T cells for cardiovascular diseases

Front Immunol. 2023 Feb 23:14:1126761. doi: 10.3389/fimmu.2023.1126761. eCollection 2023.

Abstract

Cardiovascular diseases (CVDs) are the leading cause of death and disability worldwide. The CVDs are accompanied by inflammatory progression, resulting in innate and adaptive immune responses. Regulatory T cells (Tregs) have an immunosuppressive function and are one of the subsets of CD4+T cells that play a crucial role in inflammatory diseases. Whether using Tregs as a biomarker for CVDs or targeting Tregs to exert cardioprotective functions by regulating immune balance, suppressing inflammation, suppressing cardiac and vascular remodeling, mediating immune tolerance, and promoting cardiac regeneration in the treatment of CVDs has become an emerging research focus. However, Tregs have plasticity, and this plastic Tregs lose immunosuppressive function and produce toxic effects on target organs in some diseases. This review aims to provide an overview of Tregs' role and related mechanisms in CVDs, and reports on the research of plasticity Tregs in CVDs, to lay a foundation for further studies targeting Tregs in the prevention and treatment of CVDs.

Keywords: cardiac regeneration; cardiac remodeling; cardiovascular diseases; immune balance; immune tolerance; inflammation; regulatory T cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases*
  • Humans
  • Immune Tolerance
  • Immunosuppressive Agents
  • T-Lymphocytes, Regulatory*

Substances

  • Immunosuppressive Agents
  • Biomarkers

Grants and funding

The work was supported by the Three-year Action Plan of Shanghai Shenkang Medical Development Center (Grant/Award Number: SHDC2020CR1053B); the National Natural Science Foundation of China (Grant/Award Number: 82274306, 82204859, 81973656).